InNexus Appoints Head of Research
November 18 2005 - 11:53AM
PR Newswire (US)
TSX.V: IXS, OTCBB: IXSBF VANCOUVER, Nov. 18 /PRNewswire-FirstCall/
-- InNexus Biotechnology, Inc. is pleased to announce the
appointment of Dr. Heinz Kohler to Vice-President of Research. He
will assume this role immediately and is the original inventor of
SuperAntibody(TM) Technology. Dr. Kohler has been the Company's
Acting Head of Research and Development. Dr. Kohler was
instrumental in the start-up phase of one of the most successful
biotech companies, IDEC Pharmaceuticals, as the Director of
Research and holds both an MD and Ph.D. degree. He is world
renowned in the development of monoclonal antibodies and has
authored and contributed to over 200 peer-reviewed publications and
is listed as Inventor on numerous inventions and patents. Dr.
Kohler has previously held the roles of Professor at the University
of Chicago, the University of SUNY at Buffalo, the University of
California San Diego and Director of Molecular Immunology at the
Roswell Park Cancer Center. He also helped to found Immpheron Inc.
of Lexington, Kentucky, which currently manages InNexus' Coldstream
Research Laboratory. About InNexus InNexus is an innovative
antibody-driven drug development company that has developed two
technology platforms, SuperAntibody(TM) and TransMAbs(TM), which
improve the potency of existing antibody products while opening new
markets and disease applications. Both platforms utilize unique,
novel and patented methods and technologies of InNexus. InNexus is
headquartered in British Columbia, Canada and has its own in-house
developmental facilities. These development facilities provide
validation of protein and peptide discoveries, enabling InNexus
(and its strategic partners) to advance novel drug therapeutics and
diagnostics. To learn more about InNexus please visit
http://www.innexusbiotech.com/. This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements are not
historical facts and are subject to risks and uncertainties which
could cause actual results and the timing of certain events to
differ materially from those set forth in or implied herein
including, without limitation, risks associated with clinical
development, regulatory approvals, product commercialization,
intellectual property claims litigation and other risks associated
with the Company's proposed activities. On behalf of the Board of
Directors of InNexus Biotechnology, Inc. Dr. A. Charles Morgan
President To contact us: Telephone: (877) 990-8382 Fax: (425)
696-0068 Email: Investor Relations: Telephone: (866) 990-8382
Email: The TSX Venture Exchange has neither approved nor
disapproved of the information contained herein. DATASOURCE:
InNexus Biotechnology, Inc. CONTACT: Telephone: (877) 990-8382,
Fax: (425) 696-0068, Email: ; Investor Relations: Telephone: (866)
990-8382, Email:
Copyright